Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

89 results about "Phagocytic Cell" patented technology

A type of immune cell that can surround and kill microorganisms, ingest foreign material, and remove dead cells. It can also boost immune responses. Monocytes, macrophages, and neutrophils are phagocytes. A phagocyte is a type of white blood cell.

Non-hepatic targeting type nucleic acid drug delivery system based on electrostatic / chemical coupling dual anchoring effect and preparation method and application of non-hepatic targeting type nucleic acid drug delivery system

The invention relates to a nano delivery material, and discloses a non-hepatic targeting nucleic acid drug delivery system based on electrostatic / chemical coupling dual anchoring effect, and a preparation method and application thereof. The carrier comprises a carrier core and a carrier shell, wherein the carrier core is composed of a lipid nanocomposite and nucleic acid molecules, and the carrier shell is composed of albumin with good biocompatibility. According to the invention, the albumin shell is efficiently coated on the surface of the carrier core through electrostatic / chemical coupling dual anchoring action, so that the cytotoxicity caused by the nano-composite core can be reduced, and meanwhile, the carrier core is protected from being efficiently loaded with nucleic acid drugs and the nucleic acid drugs are ensured not to be degraded. In addition, the albumin shell can avoid recognition of mononuclear phagocyte systems such as liver and spleen, so that the nucleic acid delivery system is endowed with excellent non-liver targeting property, and toxic and side effects on normal cells and tissues of the liver can be avoided when the nucleic acid delivery system is applied in vivo.
Owner:CHINA PHARM UNIV

Ganoderma lucidum fermentation liquor capable of improving content of total triterpenes and improving immunity as well as preparation method and application of ganoderma lucidum fermentation liquor

The invention discloses a ganoderma lucidum fermentation liquid capable of improving the content of total triterpenes and immunity and a preparation method and application thereof, the preparation method comprises the following steps: heating a ganoderma lucidum liquid, and carrying out hot water extraction to obtain a ganoderma lucidum extracting liquid; heating the lucid ganoderma extracting solution to be boiled, after sterilization is finished, after the lucid ganoderma liquid is cooled, adding lactic acid bacteria powder in a specific proportion for fermentation to obtain lucid ganoderma fermentation liquid; and carrying out solid-liquid separation on the fermentation liquor to obtain fermentation supernate, and sterilizing the ganoderma lucidum fermentation liquor to obtain the sterilized ganoderma lucidum fermentation liquor. According to the preparation method disclosed by the invention, the content of total triterpenes in the ganoderma lucidum fermentation liquor is increased, the immunomodulatory activity of the ganoderma lucidum product can be enhanced, and the ganoderma lucidum product has relatively high effects of resisting oxidation, improving the activity of phagocytes, improving the activity of acid phosphatase, improving the immunity and the like, and has a wide application prospect and market potential.
Owner:XIAMEN YUANZHIDAO BIOTECHNOLOGY CO LTD

Lipopolysaccharide response type nano antibacterial peptide as well as preparation method and application thereof

The invention discloses a lipopolysaccharide response type nano antibacterial peptide as well as a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID No.1. Meanwhile, the invention further discloses application of the antibacterial peptide in preparation of drugs for treating gram-negative bacterium infectious diseases. The antibacterial peptide disclosed by the invention can be combined with lipopolysaccharide in a targeted manner to form nanofibers for capturing, and then the nanofibers are clustered and presented to phagocytes for phagocytosis, so that killing of beneficial bacteria in a host is fully avoided. In conclusion, the antibacterial peptide disclosed by the invention can target gram-negative bacteria to rupture membranes and sterilize, fully avoid mistakenly killing beneficial bacteria in a host body and effectively reduce the generation of drug resistance, so that the antibacterial peptide is a nano capture peptide with an immune regulation function, which has great development potential and relatively high application value.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Cells differentiated from immunoengineered pluripotent cells

PendingUS20250283051A1Senses disorderNervous disorderHeart cellsCells islets
The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.
Owner:RGT UNIV OF CALIFORNIA

Neutrophile granulocyte intercellular effect-mediated high-efficiency mononuclear phagocyte targeting siRNA (small interfering Ribonucleic Acid) nanoparticle as well as preparation method and application thereof

The invention discloses siRNA (small interfering Ribonucleic Acid) nanoparticles capable of efficiently targeting mononuclear phagocytes and mediated by intercellular effect of neutrophils as well as a preparation method and application of the siRNA nanoparticles. The siRNA nanoparticles comprise mesoporous silica nanoparticles carrying siRNA, and functional cell membranes over-expressing ICAM-1 ligands are wrapped outside the mesoporous silica nanoparticles carrying siRNA. Key sentinel cells (mononuclear phagocytes, MPs) for targeted mitochondrial DNA release to treat inflammatory responses caused by mtDNA. The efficient delivery of MPs is realized by using a functionalized cell membrane of an overexpressed ICAM-1 ligand to wrap nano-particles and by virtue of infiltration and rapid apoptosis of a large number of neutrophils in an inflammatory microenvironment and a process (cell burial effect) of specific phagocytosis of the neutrophils by the MPs. Compared with a traditional targeting scheme, the in-vitro targeting efficiency and the in-vivo targeting efficiency of the FCM-coated siNPs scheme are improved by 360% and 120% respectively. The siRNA is guided to target MPs, and the expression of STING is inhibited, so that the inflammatory reaction caused by mtDNA release is regulated and controlled, and an excellent anti-inflammatory curative effect is shown in an inflammatory model mouse.
Owner:STOMATOLOGICAL HOSPITAL OF CHONGQING MEDICAL UNIV

Injectable filling microsphere, injectable filling material containing injectable filling microsphere, and preparation and application of injectable filling material

The invention discloses an injectable filling microsphere, an injectable filling material containing the injectable filling microsphere and preparation and application of the injectable filling microsphere. The preparation method of the injectable filling microspheres comprises the following steps: an organic phase comprises a PLA-PEG-PLA block copolymer and an organic solvent; the water phase comprises a surfactant and water; the organic phase and the water phase are mixed, and injectable filling microspheres are prepared through membrane emulsification and curing; wherein the viscosity of the water phase is 4 to 25 mPa.s; and the pore diameter of a membrane tube in the membrane emulsification process is 35-65 microns. The injectable filling microspheres prepared by the method disclosed by the invention are small in particle size span, and the particle size distribution of more than 90% of microspheres can be ensured to be 20-50 [mu] m. The method has the advantages of high target particle size microsphere yield, simple operation, low production cost, low injection difficulty and low infection risk. Meanwhile, the particle size of the prepared microspheres meets the requirements of medical beauty products, the microspheres can be prevented from being cleared by phagocytes, the ideal degradation time in vivo can be ensured, and the use safety and bioavailability are relatively high.
Owner:BEIJING MEIYAN SPACE BIOMEDICINE CO LTD

GAS6 fusion protein as well as preparation method and application thereof

The invention provides a GAS6 fusion protein as well as a preparation method and application thereof. The provided fusion protein comprises scFv capable of specifically recognizing tumor cell antigens, tumor cells are disguised as apoptotic cells, and phagocytes phagocytize the tumor cells through interaction with TAMRTK. The provided GAS6 fusion protein can be suitable for phagocytosis of various tumor cells and has strong broad spectrum.
Owner:SUZHOU ROCROCK NO 1 BIOTECHNOLOGY CO LTD

Sherlock assays for tick-borne diseases

Provided herein is a nucleic acid detection system comprising a detection CRISPR system having an effector protein and one or more guide RNAs each designed to bind to corresponding target molecules that are diagnostic for a tick-borne disease state; and an RNA-based masking construct. In some embodiments, the detection system of may comprise i) two or more CRISPR systems, each CRISPR system comprising an effector protein and a guide RNA designed to bind to a corresponding target molecule that is diagnostic for a tick-borne disease state; and ii) a set of detection constructs, each detection construct comprising a cutting motif sequence that is preferentially cut by one of the activated CRISPR effector proteins. Exemplary tick-borne detectable microbes include Babesia microti, Anaplasma phagocytophilum, and Borrelia miyamotoi.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2

Construct having SIRP-alpha domain or variant thereof

To provide a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than wild-type SIRP-α (signal-regulatory protein α), which is useful to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof.SOLUTION: The present invention provides a polypeptide, comprising: a SIRP-α D1 variant comprising a SIRP-α D1 domain, or a fragment thereof, having an amino acid mutation at residue 80 relative to a wild-type SIRP-α D1 domain; and at least one additional amino acid mutation relative to a wild-type SIRP-α D1 domain at a residue selected from the group consisting of: residue 6, residue 27, residue 31, residue 47, residue 53, residue 54, residue 56, residue 66, and residue 92.SELECTED DRAWING: Figure 3
Owner:ALX ONCOLOGY INC

Chimeric bait receptors and uses thereof

Provided herein are novel chimeric polypeptides that bind to antigen peptides (e.g., viral antigens or tumor associated antigens) and activate the endogenous phagocytosis signaling pathway. Also provided are compositions and methods for producing such chimeric polypeptides, nucleic acids encoding such chimeric polypeptides, phagocytes that have been modified to express such chimeric polypeptides, and methods for treating various conditions, such as viral infections or cancer.
Owner:HEMOGENYX PHARMACEUTICALS LLC

Antibody Cocktails for the Treatment of Viral Infections

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.
Owner:LONGHORN VACCINES & DIAGNOSTICS LLC

Coupling molecule with effect of promoting macrophages to selectively swallow extracellular goods as well as preparation method and application of coupling molecule

The invention discloses a coupling molecule with an effect of promoting macrophages to selectively swallow extracellular goods as well as a preparation method and application of the coupling molecule, and belongs to the technical field of biological medicines. The coupling molecule disclosed by the invention is a double-targeting polypeptide and consists of a macrophage targeting peptide fragment, a linker and a target cell targeting peptide fragment, wherein the target cell targeting peptide fragment comprises peptide fragments targeting tumor cells and apoptotic cells. One end of the dual-targeting polypeptide is connected with macrophages, the other end of the dual-targeting polypeptide is connected with tumor cells / apoptotic cells, and the interaction between the macrophages and the tumor cells / apoptotic cells is improved in a molecular glue mode. Aiming at tumor cells, the dual-targeting polypeptide can enhance the phagocytosis and killing effects of macrophages on the tumor cells under the action of a CD47 antibody, so that the anti-tumor effect is achieved; aiming at apoptotic cells, the dual-targeting polypeptide can promote the interplant effect of macrophages, so that the anti-inflammatory effect is achieved. Therefore, the dual-targeting polypeptide disclosed by the invention has relatively good drug development potential.
Owner:UNIV OF MACAU

Application of an immunomodulatory peptide in the preparation of drugs for preventing and treating bacterial infections

The present invention discloses an application of an immunomodulatory peptide in the preparation of a drug for preventing and treating bacterial infection, and belongs to the field of biomedical technology; the rice-derived immunomodulatory peptide RDP3 can inhibit bacterial infection in mice, and can alleviate the inflammatory damage of the lung tissue of infected mice and reduce the level of inflammatory factor protein in the serum of infected mice to a certain extent, and can also improve the survival rate of sepsis model mice. RDP3 exerts an antibacterial effect by recruiting phagocytes to the infected site. In view of the unique antibacterial mechanism of RDP3, it can provide a basis for the research and development of RDP3 as a polypeptide anti-infective drug, and provide candidate molecules for the research and development of peptide antibiotics.
Owner:GENERAL HOSPITAL OF NUCLEAR IND

Preparation method and application of polygonatum cyrtonema polysaccharide liposome with immunomodulatory effect

The invention discloses polygonatum cyrtonema polysaccharide lipidosome with an immunoregulation effect as well as a preparation method and application of the polygonatum cyrtonema polysaccharide lipidosome. The polygonatum cyrtonema polysaccharide lipidosome is mainly prepared from polygonatum cyrtonema polysaccharide, soybean lecithin and cholesterol. The polygonatum cyrtonema polysaccharide lipidosome with the immunoregulation function is good in stability, capable of slowly releasing polygonatum cyrtonema polysaccharide and easy to prepare in an enlarged mode. Experiments prove that the polygonatum cyrtonema polysaccharide lipidosome can promote proliferation of phagocytes of mice and increase spleen and thymus indexes of immunosuppressive mice, and has an immunoregulation effect.
Owner:WEST ANHUI UNIV

Gas6 fusion protein, preparation method therefor and use thereof

Provided are a GAS6 fusion protein, a preparation method therefor and the use thereof. The provided fusion protein contains an scFv capable of specifically recognizing tumor cell antigens, and can disguise tumor cells as apoptotic cells and enable phagocytosis of tumor cells by phagocytes by means of interaction with TAM RTK. The provided GAS6 fusion protein is applicable for phagocytosis of various tumor cells, showing strong broad-spectrum properties.
Owner:SUZHOU ROCROCK NO 1 BIOTECHNOLOGY CO LTD

CXCL-BPI fusion protein and use thereof

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.
Owner:BEIJING ANJUN GENETECH CO LTD +1

IBD egg yolk antibody microspheres and preparation method thereof

The present invention belongs to the technical field of yolk antibody preparation, and specifically relates to an IBD yolk antibody microsphere and a preparation method thereof. The method uses polygonatum polysaccharide, IBD yolk antibody and bupleurum essential oil as the inner phase of the microsphere, and polylactic-co-glycolic acid copolymer as the outer phase. The special structure of the microspheres prepared by the present invention is conducive to presenting yolk antibodies and polygonatum polysaccharide to immune-competent cells. Phagocytic cells engulf the microspheres and can destroy the shell structure of the microspheres, releasing yolk antibodies and polygonatum polysaccharide, neutralizing the IBD virus infected by the body, playing a preventive and protective role for chickens not infected with IBD, and quickly controlling the condition of chickens infected with IBD.
Owner:SHANGQIU MEILAN BIOENGINEERING CO LTD

Traditional Chinese medicine composition for promoting ablation of atherosclerotic plaque and pulmonary nodule as well as preparation method and application of traditional Chinese medicine composition

The invention provides a traditional Chinese medicine composition for promoting ablation of atherosclerotic plaques and pulmonary nodules as well as a preparation method and application of the traditional Chinese medicine composition, and belongs to the technical field of disease treatment medicines. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: semen ziziphi spinosae, rhizoma atractylodis macrocephalae, arillus longan, flos carthami, apricot kernels, cordyceps militaris, herba cistanche, radix astragali, rhizoma polygonati, ginseng, peach kernels, fructus lycii, orange peel, radix platycodonis, radix angelicae sinensis, radix ophiopogonis, fructus hordei germinatus and fructus ziziphi jujubae. The traditional Chinese medicine composition provided by the invention has the main effects of tonifying qi, enriching blood and tonifying liver and kidney, improves the circulation metabolism function of the body, exerts the effects of strengthening bones and generating marrow, and finally can promote the generation of immune phagocytes and cholesterol esterase by cooperating with the effects of promoting blood circulation, removing blood stasis and dredging collaterals; ablation of atherosclerotic plaques and pulmonary nodules is promoted from multiple ways, multiple links and multiple targets.
Owner:BEIJING YONGKANGNIAN HEALTH TECH CO LTD

CD47 targeted therapies for the treatment of infectious disease

Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +2

Cxcl-bpi fusion proteins and uses thereof

The application discloses a CXCL-BPI fusion protein which can be used for treating gram-negative bacterial infection, a coding nucleic acid of the CXCL-BPI fusion protein, an expression preparation method, and application of the CXCL-BPI fusion protein to preparation of a pharmaceutical composition for treating gram-negative bacterial infection. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a human BPI N-terminal domain functional fragment, has the functions of combining LPS, directly killing gram-negative bacteria and chemotactic cell migration, and also has the functions of promoting phagocytes to be guided to combine and phagocytize gram-negative bacteria, and the action mechanism can overcome gram-negative bacterial drug resistance.
Owner:BEIJING ANJUN GENETECH CO LTD +1

Ex-VIVO proliferation of human phagocytic cells

The invention provides human phagocytic cells which are not tumorigenic, yet still capable of cell division ex-vivo, such as in cell culture. A culture containing these cells can be expanded manyfold, that is the cell number in such a culture can be increased by a factor of 10 or more. The cells show characteristics of functional phagocytes in a differentiated state and are capable to alleviate pathological defects in in vivo models.
Owner:TECHNISCHE UNIVERSITAT DRESDEN +3

Engineered cell and use

PCT designated stage expiredWO2025092626A1Antibacterial agentsCulture processImmunocompetencePhotosensitizing compounds
An engineered cell and a use, belonging to the technical field of fine chemical engineering. A photosensitive compound is loaded into a phagocyte, a bacterium in a host is captured by utilizing the innate immunity of the cell, and thus by means of light treatment, the bacterium is killed. Compared with the limitation that a conventional photosensitizer cannot target a living bacterium, the cell formulation can precisely capture a bacterium by means of a macrophage and precisely "deliver" a photosensitive dye to the surface of the bacterium. Therefore, the light treatment can directly act on the surface of the bacterium without damaging an autologous tissue in a patient and has high sterilization efficiency and good treatment safety.
Owner:DALIAN UNIV OF TECH

Single-cell profiling of phagocytosis using microscopy

The invention relates to methods of evaluating phagocytosis at a single-cell level by placing one or more phagocytes and one or more particles on a surface and visualizing the phagocytosis of the particles by the phagocytes. The invention also relates to systems for evaluating phagocytosis of a particle by a phagocyte at a single-cell level.
Owner:UNIV HOUSTON SYST

Hierarchical diagnosis method for pathogenesis of lymphocytosis of phagocytic cells

The invention belongs to the technical field of biomedical research, and particularly relates to a hierarchical diagnosis method for pathogenesis of hemophagocytic lymphocytosis, which comprises the following steps: S1, collecting peripheral blood samples of a plurality of secondary HLH patients, and carrying out pathogenesis clinical grouping on each secondary HLH patient; s2, carrying out mNGS detection on the peripheral blood sample, establishing an innovative analysis strategy and method based on mNGS data, and carrying out integrated analysis and key evaluation parameter screening on patient chromosome copy number variation (CNV) data and microorganism data generated by mNGS. A set of clinical evaluation model for performing layered diagnosis on complex etiology such as infection, tumor and autoimmunity on HLH patients is established, etiology accurate screening and auxiliary layered diagnosis can be performed on clinically diagnosed secondary HLH patients, the economic cost and time cost of disease diagnosis are greatly reduced, and clinical accurate diagnosis and treatment and patient benefit are facilitated.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV +1

Methods for determining the level of immune rejection between allogeneic cells, tissues or organs

The present disclosure provides a method for judging the level of immune rejection between heterologous cells, tissues or organs, and relates to the field of biological medicine. The method provided by the present disclosure can quickly and objectively compare the interspecies relative phagocytosis rate of phagocytes in a single experiment, and provides a new way for evaluating and researching the level of immune rejection between heterologous cells, tissues or organs.
Owner:HAIHE LAB OF CELL ECOSYSTEM +1

Gene therapy

PCT designated stage expiredWO2024227946A1Peptide/protein ingredientsDsDNA virusesPhagocytic CellTr1 cell
A product comprising: (a) a vector for liver and / or splenic phagocyte-specific expression, wherein the vector comprises a transgene operably linked to one or more expression control sequence; and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.
Owner:OSPEDALE SAN RAFFAELE SRL +2

Medicine for resisting hashimoto thyroiditis disease and preparation method thereof

The invention relates to the technical field of medicine component extraction, and discloses a medicine for resisting hashimoto thyroiditis disease, the medicine comprises an active component and an auxiliary material, the active component is an andrographis paniculata general flavone extract, andrographis paniculata general flavone is used as a main component, and the andrographis paniculata general flavone can reduce exudation of capillary walls, so that the medicine can be used for preventing and treating the hashimoto thyroiditis disease. The andrographis paniculata total flavone extract has an anti-inflammatory effect, is especially effective for symptoms such as upper respiratory tract and diarrhea caused by bacteria and viruses, shows strong antibacterial and antiviral capabilities, can inhibit ADP-induced human platelet aggregation, shortens the dissolution time of euglobulin, and has a good anti-inflammatory effect. The andrographis paniculata extract has a certain protective effect on myocardial injury caused by isoprenaline and experimental myocardial infarction ischemic injury, and the andrographis paniculata extract can enhance the function of phagocytes and improve the staphylococcus aureus phagocytosis capacity of peripheral blood leukocytes, and is used for enhancing immunity and overcoming immunity diseases.
Owner:THE SECOND AFFILIATED HOSPITAL TO NANCHANG UNIV

Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (POC) diagnostic testing point-of-care (POC) measurement of absolute neutrophil function (ANF)

A method for estimating a number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive dioxygenation of a chemiluminigenic substrate by an emitted chemiluminescence of the chemiluminigenic substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes. The NADPH oxidase activity of the phagocytes is preferably stimulated by a stimulus in solution or coated to a surface contacted by the phagocytes. The stimulus is preferably phorbol myristate acetate (PMA). The animal is preferably human, and the body fluid is preferably blood and / or spinal fluid. The phagocytes are preferably neutrophil leukocytes, and the chemiluminigenic substrate is preferably lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of treatment based on the estimation method.
Owner:BINARY LLC

Anti-Dectin-1 Antibody and Method of Use Thereof

The present disclosure relates to antibodies, multispecific (e.g., bispecific) binding molecules that bind to human Dectin-1, and related methods of use and production. Disclosed herein is a method of targeted phagocytosis for removing disease-causing agents, including host cells / host cell products, microorganisms, or products thereof, by administering a multispecific (e.g., bispecific) binding molecule that comprises a Dectin-1 binding arm and a second arm that specifically binds to the agent. The multispecific (e.g., bispecific) binding molecule allows phagocytes to engage with the target agent and form a synapse between them, promoting the clustering of Dectin-1 on the phagocyte. This stimulates phagocytosis of the target agent and also stimulates cytokine secretion by the phagocyte via the Dectin-1 / Syk / NfkB pathway.
Owner:DREN BIO INC